AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2021
Sep 2, 2021
6965_dirs_2021-09-02_59de6398-a76c-4c1d-b592-82167c3a2b97.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-09-01
Reporting Person: Silberman David (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-01 | Common Stock | A | 50000 | — | Acquired | 50000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-01 | Stock Option (right to buy) | $20.19 | A | 50000 | Acquired | 2031-09-01 | Common Stock (50000) | Direct |
Footnotes
F1: Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs will vest as follows: 33,333 shall vest in three equal installments over a period of three years upon Issuer's common stock achieving a specified price per share, and 16,667 shall vest in three equal installments over a period of three years upon Issuer's achievement of certain business objectives.
F3: The Stock Options will vest in four equal installments of 12,500 on each of June 27, 2022, June 27, 2023, June 27, 2024 and June 27, 2025.